Hansa Biopharma AB (publ) (HNSBF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Hansa Biopharma has developed a first-in-class IgG-cleaving enzyme through a proprietary technology platform, which includes two different types of enzymes [3] - The enzyme effectively reduces IgG levels to less than 5% of baseline within 2 to 6 hours, targeting both intravascular and extravascular IgG [3] Product Benefits - The enzyme aims to address acute or serious immune-mediated diseases, providing a solution for highly sensitized patients awaiting kidney transplants, who face significant challenges in finding compatible organ matches [4] - Clinical data has been generated in gene therapy, focusing on cleaving antibodies related to AAV antibodies, which may enable better treatment options for affected patients [4]